


3. A compound according to the formula:



Formula I

wherein n is 1-4;

$R_1$  may be one or more optional substituents selected from the group consisting of: (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkoxy, (C2-C6)alkenyloxy, (C2-C6)alkynyloxy, (C1-C6)alkylthio, (C1-C6)alkylsulphanyl, (C1-C6)alkylsulphonyl, (C1-C6)alkylamino, di-[(C1-C6)alkyl]amino, (C1-C6)alkoxycarbonyl, N-(C1-C6)alkylcarbonyl, N,N-di-[(C1-C6)alkyl]carbonyl, (C2-C6)alkanoyl, (C2-C6)alkanoyloxy, (C2-C6)alkanoylamino, N-(C1-C6)alkyl-(C2-C6)alkanoylamino, (C3-C6)alkenoylamino, N-(C1-C6)alkyl-(C3-C6)alkenoylamino, (C3-C6)alkynoylamino, N-(C1-C6)alkyl-(C3-C6)alkynoylamino, N-(C1-C6)alkylsulphamoyl, N,N-di-[(C1-C6)alkyl]sulphamoyl, (C1-C6)alkanesulphonylamino, N-(C1-C6)alkyl-(C1-C6)alkanesulphonylamino, carboxamide, ethylene, thiophenyl, aminophenyl, trifluoromethyl, halo, trifluoromethoxy, hydroxymethyl, N-pyrrolidino, N-morpholino, phenylthio, (C1-C4)dialkylaminomethyl, methoxyphenyl, amino, hydroxy, carboxyl, phenyl, arylalkyl;

$R_2$  is selected from the group comprising oxazole; benzo[2,1,3]thiadiazole; quinoxaline; 1H-imidazo[4,5-c]pyridine; imidazo[1,2-a]pyridine; indole; pyrazine; dihydrobenzofuran; furan; thiophene; isoquinoline; benzofuran; benzothiazole; 3,4-dihydro-2H-benzo[b][1,4]dioxepine; 1H-imidazo[4,5-b]pyridine; pyrazolo[1,5-a]pyrimidine; oxazolo[4,5-b]pyridine; 1H-benzoimidazole; [1,8]naphthyridine; or [1,5]naphthyridine;

$-(CH_2)_3N(CH_3)_2$ ;

$-(CH_2)_3N(CH_2CH_3)_2$ ;

$-(CH_2)X$ ,

wherein X is either N-morpholino, N-pyrrolidine or N-piperidine;

5 and the pharmaceutically acceptable salts thereof.

7. A compound selected from the group consisting of:

- a) 2-(Pyridin-2-yl)-3-(thiophen-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- 10 b) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-indole;
- c) 3-(2-Phenyl-oxazol-5-yl)-2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole;
- d) 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-benzo[2,1,3]thiadiazole;
- 15 e) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]benzo[2,1,3]thiadiazole;
- f) 6-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxaline;
- g) 5-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoxaline;
- 20 h) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-imidazo[4,5-b]pyridine;
- i) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-imidazo[4,5-c]pyridine;
- 25 j) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazole;
- k) 2-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-oxazolo[4,5-b]pyridine;
- l) 2-Dimethylamino-N-[6-[2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-[1,8]naphthyridin-2-yl]-acetamide;
- 30 m) 4-[2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-[1,8]naphthyridine;

- k. 3-(4-fluoro-benzofuran-7-yl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - l. 7-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-isoquinoline.
  - 5 m. 1-Methyl-5-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1H-indole.
  - n. 1-Methyl-5-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-1H indole.
  - o. 3-Pyrazin-2-yl-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - 10 p. 2-(6-Methyl-pyridin-2-yl)-3-pyrazin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - q. 3-(2,3-dihydro-benzofuran-5-yl)-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - r. 3-Furan-3-yl-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - 15 s. 2-(6-Methyl-pyridin-2-yl)-3-thiophen-3-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - t. 3-benzofuran-5-yl-2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
  - 20 u. 6-(2-Pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-pyrazolo[1,5-a]pyrimidine.
  - v. 3-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole.
- 25 9. A pharmaceutical formulation comprising a compound according to any one of Claims 1 to 8 or the pharmaceutically acceptable salt, ester or prodrug thereof together with a pharmaceutically acceptable diluent or carrier.
- 30 10. Use of a compound according to any one of Claims 1 to 8 or pharmaceutically acceptable salt, ester or prodrug thereof, in the manufacture of a medicament for the treatment of cancer, fibrosis, restenosis, wound healing, HIV infection alzheimer's disease and/or atherosclerosis.

11. The method of treating cancer which comprises administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of Claims 1 to 8 or pharmaceutically acceptable salt, ester or prodrug thereof.

5        12. Use of a compound according to any one of Claims 1 to 8 or pharmaceutically acceptable salt, ester or prodrug thereof, in combination with any other anti-cancer agent in the manufacture of a medicament for the treatment of cancer.

10       13. The method of treating cancer which comprises of administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of Claims 1 to 8 or pharmaceutically acceptable salt, ester or prodrug thereof in combination with any other anti-cancer agent.